New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
08:50 EDTEXASExact Sciences CMS approval expected by early September, says Canaccord
Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
August 24, 2015
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use